These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11328924)

  • 1. Intravenous administration of iron in epoetin-treated haemodialysis patients.
    Shaldon S
    Nephrol Dial Transplant; 2001 May; 16(5):1076-7. PubMed ID: 11328924
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?
    Macdougall IC
    Nephrol Dial Transplant; 2000 Nov; 15(11):1743-5. PubMed ID: 11071957
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous low-dose iron administration in hemodialysis patients treated with erythropoietin.
    Kurihara I; Saito T; Nakayama K; Sato H
    Nephron; 1998 Nov; 80(3):369-70. PubMed ID: 9807056
    [No Abstract]   [Full Text] [Related]  

  • 4. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 6. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in intravenous iron treatment.
    Marx JJ
    Arzneimittelforschung; 2010; 60(6a):341-4. PubMed ID: 20648925
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there material hazard to treatment with intravenous iron?
    Fishbane S; Maesaka JK; Mittal SK
    Nephrol Dial Transplant; 1999 Nov; 14(11):2595-8. PubMed ID: 10534495
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
    Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel aspects of vitamin C in epoetin response.
    Tarng DC
    J Chin Med Assoc; 2007 Sep; 70(9):357-60. PubMed ID: 17908648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis.
    Goicoechea M; Caramelo C; Rodriguez P; Verde E; Gruss E; Albalate M; Ortiz A; Casado S; Valderrábano F
    Nephrol Dial Transplant; 2001 Nov; 16(11):2188-93. PubMed ID: 11682666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin.
    al-Hawas F; Abdalla AH; Popovich W; Mousa DH; al-Sulaiman MH; al-Khader AA
    Nephrol Dial Transplant; 1997 Dec; 12(12):2801-2. PubMed ID: 9430909
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous iron and chronic kidney disease.
    Auerbach M
    Am J Hematol; 2014 Nov; 89(11):1083. PubMed ID: 25219516
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.
    Hedenus M; Birgegård G; Näsman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Lärfars G; Osterborg A
    Leukemia; 2007 Apr; 21(4):627-32. PubMed ID: 17252006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.